KYDES products are developed from currently approved drug compounds and FDA approved excipients using our proprietary technologies. The products will be manufactured to meet or exceed Current Good Manufacturing Practices (CGMP) Guidelines set forth by the FDA and other Regulatory Agencies. The products listed in the menu above are in various stages of development.
Click on the products below for details.
|KY1101 & KY1102||KY1103||KY1104||KY1105||KY1106||KY1107|
KY006 is an intravenous product with anti-adherent properties being developed as an adjuvant in the treatment of drug resistant malaria, leukemia, sickle cell crisis, chemotherapy-induced micro-thrombosis and drug resistant MRSA/ VRE infections.